Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-25 pm EDT			5-day change	1st Jan Change
173 ^CNY	+2.99%		-0.76%	+32.83%

May. 22	Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	CI
May. 15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024	CI

Shenyang Xingqi Pharmaceutical to Buy 33.2% Stake in Hospital

September 29, 2021 at 04:22 am EDT

Shenyang Xingqi Pharmaceutical Co.,Ltd (SZSE:300573) said it plans to buy remaining 33.2% stake in Ophthalmology Hospital for CNY 130.5 million ($20.18 million).

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	May. 21	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024	May. 15	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	Apr. 26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	Mar. 13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	Jan. 08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	Dec. 12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	Dec. 12	CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid	Nov. 08	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023	23-09-18	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023	23-09-14	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023	23-08-29	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops	23-08-17	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Dividend for the Year 2022, Payable on 22 May 2023	23-05-12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Dividend for 2022	23-04-20	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022	22-09-16	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022	22-09-14	CI
Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022	22-08-28	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

More charts

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shenyang Xingqi Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

173

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+32.83%	4.15B
MERCK KGAA	+8.43%	72.21B
KYOWA KIRIN CO. LTD.	+14.98%	9.14B
SK BIOPHARMACEUTICALS CO., LTD.	-23.31%	4.33B
YUHAN CORPORATION	+15.70%	4.28B
INDIVIOR PLC	+9.62%	2.19B
BETTA PHARMACEUTICALS CO., LTD.	-33.37%	1.98B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.30%	1.98B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-46.20%	1.68B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Shenyang Xingqi Pharmaceutical Co.,Ltd.

Equities

300573

CNE100002DV1

Pharmaceuticals

Shenyang Xingqi Pharmaceutical to Buy 33.2% Stake in Hospital

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

Company Profile

Income Statement Evolution

Ratings for Shenyang Xingqi Pharmaceutical Co.,Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals